Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThoracSPA: bimekizumab versus adalimumab for anterior chest wall pain in active axial spondyloarthritis
2025-520632-42-00Phase 3Authorised
- Sponsor
- Rouen University Hospital
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in axial spondyloarthritis (axSpA) comparing Bimekizumab arm with Adalimumab arm (2 arms). Primary endpoint: ASAS40 response at 6 months. Planned start Apr 2026; status: authorised.
02
Drugs
bimekizumabadalimumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2025-520632-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520632-42-00.